ATC Group: N06DX01 Memantine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06DX01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06D Anti-dementia drugs
4 N06DX Other anti-dementia drugs
5 N06DX01 Memantine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 20 mg

Active ingredients in N06DX01

Active Ingredient Description
Memantine

Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

Related product monographs

Title Information Source Document Type  
AXURA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
EBIXA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
EBIXA Oral solution European Medicines Agency (EU) MPI, EU: SmPC
NEMDATINE Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Canada (CA)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.